Arafat Maram, Sperling Ruth
Department of Genetics, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
Cancers (Basel). 2022 Mar 30;14(7):1750. doi: 10.3390/cancers14071750.
Latent 5' splice sites, highly abundant in human introns, are not normally used. This led to the proposal of a quality control mechanism, Suppression of Splicing (SOS), which protects cells from splicing at the numerous intronic latent sites, and whose activation can generate nonsense mRNAs. SOS was shown to be independent of Nonsense-Mediated mRNA Decay (NMD). Efforts to decipher the SOS mechanism revealed a pivotal role for initiator-tRNA, independent of protein translation. Recently, nucleolin (a multifunctional protein) was found to directly and specifically bind the initiator-tRNA in the nucleus and was shown to be a protein component of SOS, enabling an updated model of the SOS mechanism. Importantly, SOS is abrogated under stress and in cancer (e.g., in breast cancer cells and gliomas), generating thousands of nonsense mRNAs due to activation of latent splicing. The resulting affected human genes cover a variety of functional groups, including genes involved in cell proliferation and differentiation. Furthermore, in oligodendroglioma, the extent of activation of latent splicing increases with the severity of the cancer. Interesting examples are genes expressing aberrant nonsense mRNAs in both breast cancer and glioma, due to latent splicing activation. These findings highlight the unexplored potential of such aberrant isoforms as novel targets for cancer diagnosis and therapies.
潜在的5'剪接位点在人类内含子中高度丰富,通常不被使用。这导致了一种质量控制机制——剪接抑制(SOS)的提出,该机制可保护细胞免受众多内含子潜在位点的剪接影响,其激活可产生无义mRNA。研究表明,SOS独立于无义介导的mRNA降解(NMD)。对SOS机制的解密工作揭示了起始tRNA的关键作用,这一作用独立于蛋白质翻译。最近,核仁素(一种多功能蛋白质)被发现可在细胞核中直接且特异性地结合起始tRNA,并被证明是SOS的一种蛋白质成分,从而形成了SOS机制的更新模型。重要的是,SOS在应激状态下和癌症中(如乳腺癌细胞和神经胶质瘤中)会被废除,由于潜在剪接的激活会产生数千种无义mRNA。由此产生的受影响人类基因涵盖了各种功能组,包括参与细胞增殖和分化的基因。此外,在少突胶质细胞瘤中,潜在剪接的激活程度随癌症严重程度的增加而增加。有趣的例子是在乳腺癌和神经胶质瘤中均因潜在剪接激活而表达异常无义mRNA的基因。这些发现凸显了此类异常异构体作为癌症诊断和治疗新靶点的未被探索的潜力。